Gastroenterologie
a hepatologie

Iron substitution in sideropenia or sideropenic anemia in patients with IBD with heme iron containing preparation

Martin Vašátko¹, Veronika Pešinová², Karin Malíčková ^{Orcid.org  1,3}, Naděžda Machková ^{Orcid.org  1}, Veronika Hrubá¹, Martin Lukáš ^{Orcid.org  1}, Martin Kolář¹, Milan Lukáš ^{Orcid.org  1}

+ Affiliation
¹ IBD clinical and research centre ISCARE a.s., Prague, Czech Republic
² Klinické a výzkumné centrum pro střevní záněty ISCARE a.s. a 1. LF UK Praha
³ Institute of Medical Biochemistry and Laboratory Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic

Summary

Introduction:
Sideropenia and sideropenic anemia occurring in more than a half of patients suffering from inflammatory bowel disease (IBD). The efficacy in replenishing of the iron storage or therapy of sideropenic anemia is part of the national guidelines for IBD population. Unfortunately, in IBD patients, therapy with inorganic iron preparations is associated with intolerance or side effects which occurred relatively often.
Methods and results:
A cohort of 43 IBD patients without inflammatory activity (31 with Crohn’s disease and 12 with ulcerative colitis) with sideropenia (ferritin level < 30 µg/L) or mild sideropenic anemia (hemoglobin 100 g/L–120 g/L) were recruited for 12 weeks therapy with GlobiFer®forte tablet containing heme iron and also inorganic iron. The median hemoglobin concentration significantly increased from week 0 to week 12 (123.5 g/L to 133.5 g/L) (P = 0.004) and median mean red cell corpuscular volume changed from 85.2 fL at week 0 to 87.3 fL at week 12 (P = 0.05). GlobiFer®forte was very well tolerated and side effects occurred only in one patient.
Conclusion:
The heme iron which is part of GlobiFer®forte was very well tolerated and this therapy led to the normalization of hemoglobin concentration and mean red cell volume at the end of the therapy.

Keywords

inflammatory bowel disease, hemové železo, sideropenie, sideropenní anémie

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Bayraktar UD, Bayraktar S. Tretament of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol 2010; 16 (22): 2720–2725. doi: 10.3748/wjg.v16.i22.2720.
2. Lukáš M. Hemové železo v substituci sideropenie a sideropenní anémie. Gastroent Hepatol 2019; 73 (3): 271–272. doi: 10.14735/amgh2019271.
3. GlobiFer forte: Příbalový leták o přípravku.
4. Slíva J. Železo a jeho využití v organismu. Remedia 2013; 23 (5): 254–257.
5. Hrdlička L, Kohout P, Liberda M et al. Doporučený postup pro diagnostiku a léčbu anémie u IBD. Gastroent Hepatol 2012; 66 (4): 280–285.
6. Barragán-Ibañeza G, Santoyo-Sánchez A, Ramos-Peñafiel CO. Iron deficiency anaemiaAnaemia por deficiencia de hierro. Revista Médica del Hospital General de México 2016; 79 (2): 88–97. doi: 10.1016/j.hgmx.2015.06.008.
7. Slíva J. Suplementace železem: na formě záleží. [online]. Dostupné z: http: / / wp.interna-cz.eu/ suplementace-zelezem-na-forme-zalezi.